FAILED TRIAL: Ph 3 XPORT-EC-042 Trial of Selinexor in Endometrial Cancer Did Not Meet the Primary Endpoint of PFS improvement August 5, 2026
MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients August 5, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 28, 2026
TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line R/R multiple myeloma July 28, 2026
Sonesitatug vedotin demonstrated statistically significant OS improvement in 2L+ CLDN18.2-positive advanced gastric/GEJ cancers July 28, 2026
Confirmed Durable Partial Response in Ph 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy July 28, 2026
FAILED TRIAL: Ph 3 EPCORE® DLBCL-1 Trial of Epcoritamab in Patients with R/R DLBCL failed to meet primary OS endpoint July 28, 2026
Encouraging First OS Data from 1L Higher-Risk (HR) MDS Patients in the BEXMAB Ph 1/2 Trial Announced July 28, 2026
Ph 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with indolent NHL in the watch-and-wait setting July 28, 2026
Preliminary data from Ph 2 MRD translational clinical trial of IMNN-001 + SOC N/ACT & bevacizumab in women with 1L advanced ovarian cancer announced July 28, 2026
Positive Data Demonstrating 100% ORR and 18.2-Month Median OS with Alpha DaRT + Pembrolizumab combo in Locally Advanced or Metastatic Head and Neck Cancer Reported July 28, 2026
Durable Clinical Activity of Darlifarnib + Cabozantinib Reported in Cabozantinib-Naïve Clear Cell RCC Patients July 28, 2026
Ivonescimab + Chemo Shows Consistent, Favorable OS Results in Western and Asian Patients in Updated Analysis from Global Ph 3 HARMONi Study July 28, 2026
Interim Safety Data in Ph 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients Reported July 22, 2026
Ph 3 Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as 1L PD-L1-Neg Non-Squamous NSCLC Met Primary Endpoint July 22, 2026
KEYTRUDA Monotherapy Significantly Improved PFS vs chemo in Certain Patients With Advanced or Recurrent MMR-deficient Endometrial Cancer July 22, 2026
Ph 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors published in the JCO July 21, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 21, 2026
Encouraging Preliminary Data from Ongoing Ph 2 Study of BPM31510 in Newly Diagnosed GBM Reported July 21, 2026
Strong Initial Efficacy Data Reported in 3L NSCLC from Ph 2 THIO-101 Part C Expansion Trial July 15, 2026
Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer July 15, 2026
Global Ph 3 study of HBI-8000 plus nivolumab met the PFS primary endpoint in frontline patients with advanced melanoma July 15, 2026
Publication in The JCO Demonstrating DeltEx DRI Doubles PFS in Newly Diagnosed Glioblastoma July 15, 2026
Results from ELEVATE study of postoperative adjuvant ensartinib in stage IB–IIIB (T3N2M0) ALK-positive NSCLC published in NEJM July 15, 2026
